ClinicalTrials.gg
CompletedNCT00667446Updated Jan 9, 2014Results posted

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

A Phase 3 interventional study of Leuprolide Acetate 3 Month Depot in Precocious, Leuprolide Acetate and Luteinizing Hormone (LH), sponsored by AbbVie (prior sponsor, Abbott). Completed at 20 sites in 2 countries. Per ClinicalTrials.gov, last updated 2014-01-09.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Enrollment
7th of 14
72 · median 68
Started
2008
with 1 other
Phase 3
6 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
1 of 14
AbbVie (prior sponsor, Abbott)

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 3rd registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).

Read the detailed description

This study includes a 36-month Study Drug Treatment Period (3-month treatment cycles), and a Safety Follow-up Period (12 weeks following the Month 36 visit). Participants will receive a total of twelve injections of the same treatment they received in the lead-in study, L-CP07-167 (NCT00635817) either leuprolide acetate 11.25 mg or 30 mg depot formulation. Each injection will be administered 3 months apart for up to 36 months of treatment. Study visits will occur on Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 and 33 (1st through the 12th leuprolide acetate depot injections, respectively), Month 36, and 12 weeks later for the Safety Follow-up Visit.

03

Conditions studied

  • Precocious
  • Leuprolide Acetate
  • Luteinizing Hormone (LH)
  • Gonadotrophin-releasing Hormone Agonist (GnRHa)
  • Tanner Staging
  • Depot Formulation
  • Suppression of LH
  • Central Precocious Puberty (CPP)
  • Gonadotrophin-releasing Hormone (GnRH)
  • Lupron
  • GnRH Analog
  • Pediatrics Central Precocious Puberty

Browse trials for

Keywords

  • GnRH analog
  • Luteinizing hormone (LH)
  • Gonadotrophin-releasing hormone agonist(GnRHa)
  • Suppression of LH
  • Gonadotrophin-releasing hormone (GnRH)
  • CPP
  • Leuprolide acetate
  • Central Precocious Puberty
  • Depot formulation
  • Lupron
  • Tanner staging
  • Pediatrics
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed the Treatment Period of the lead-in study, L-CP07-167 (NCT00635817), and has documented luteinizing hormone suppression as evidenced by peak-stimulated luteinizing hormone \<4 mIU/mL at the Month 6 study visit of the lead-in study.
  • Demonstrated suppression of the physical signs of puberty at Month 6 of the lead-in study.
  • Subject is expected to receive at least 12 months of therapy to treat Central Precocious Puberty after study entry.
  • In general good health with no uncontrolled, disease which would interfere with bone maturation or mask the objectives of this protocol as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Incomplete precocious puberty, peripheral precocious puberty or evidence of any abnormal pituitary, hypothalamic, adrenal, thyroid and gonadal function (other than premature secretion of gonadotropins) not adequately controlled, unstable intracranial tumors except hamartoma.
  • Bone age ≥14 years for girls and ≥15 years for boys (based on the Month 6 lead in study, L-CP07-167, radiographic results).
  • Has an abnormal laboratory value suggesting a underlying disease or condition.
  • Chronic illness requiring treatment that may interfere with growth, ie, chronic use, renal failure, moderate to severe scoliosis.
  • Current therapy with medroxyprogesterone acetate.
  • Current therapy with growth hormone.
  • Current therapy with insulin-like growth factor-1 (IGF-1).
  • Current use of an estrogen preparation.
  • Any concomitant medical condition that, in the opinion of the investigator, may expose a subject to an unacceptable level of safety risk or that affects subject compliance.
  • Subject has a positive pregnancy test.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Leuprolide Acetate 3M Depot 11.25 mg

    Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.

    Drug: Leuprolide Acetate 3 Month Depot

  • Experimental
    Leuprolide Acetate 3M Depot 30 mg

    Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.

    Drug: Leuprolide Acetate 3 Month Depot

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone

    Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \< 4 mIU/mL. Peak-stimulated LH refers to the maximum LH concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Participants who failed suppression at previous visit and prematurely discontinued were counted as having failed future visits also. Final visit is the participant's last visit closest to Month 36.

    Time frame: Day 1, Months 6, 12, 24, and 36

Secondary outcomes

  1. Percentage of Female Participants With Suppression of Basal Estradiol (Assay 1)

    The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed before this change occurred, with an LLOQ of 1 pg/mL. Final visit is the participant's last visit closest to Month 36.

    Time frame: Day 1, Months 3, 6, 9, 12, and 24

  2. Percentage of Female Participants With Suppression of Basal Estradiol (Assay 2)

    The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed after this change occurred, with an LLOQ of 10 pg/mL. Final visit is the participant's last visit closest to Month 36.

    Time frame: Months 6, 9, 12, 24, 30, and 36

  3. Percentage of Male Participants With Suppression of Basal Testosterone

    The percentage of male participants with suppression of basal testosterone to prepubertal levels, defined as testosterone \< 30 ng/dL. Final visit is the participant's last visit closest to Month 36.

    Time frame: Day 1, Months 3, 6, 9, 12, 24, 30, and 36

  4. Mean Peak-stimulated Luteinizing Hormone Concentration by Visit

    Peak-stimulated luteinizing hormone refers to the maximum luteinizing hormone concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Final visit is the participant's last visit closest to Month 36.

    Time frame: Baseline of the lead-in study L-CP07-167, Day 1, Months 6, 12, 24, and 36

  5. Percentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)

    The percentage of female participants with suppression of breast development. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression of breast development is defined as regression or no progression of breast development from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.

    Time frame: Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36

  6. Percentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)

    The percentage of male participants with suppression of testicular volume and genital staging. Testicular volume was calculated from the length, width and height of each testicle measured by ultrasound. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression is defined as regression or no progression in both testicular volume and genital staging from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.

    Time frame: Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36

  7. Change From Baseline in Growth Rate

    Baseline growth rate was the growth rate in the one year prior to Day 1 of the lead-in study L-CP07-167. Growth rates were calculated as the ratio of the change in height to the change in chronological age with an approximate 6-month interval for Day 1, Months 6, 12, 18, 24, 30, 36 and the Final Treatment Visit.

    Time frame: Baseline (the 1 year prior to the start of treatment in the lead-in study), and Day 1, Months 6, 12, 18, 24, 30, and 36

  8. Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age

    Bone age was determined by left hand/wrist bone age radiographs that were evaluated using the Fels Method by a central reader. The ratio of change from Baseline in bone age (BA)/change from Baseline in chronological age (CA) was calculated using the following formula: (BA at Post-baseline Treatment Visit - BA at Baseline) / (CA at Post-baseline Treatment Visit - CA at Baseline).

    Time frame: Baseline (of the lead-in study L-CP07-167), and Day 1, Months 12, 24, and 36

07

Results

Posted Dec 10, 2013

Participant flow

Participants who successfully completed and showed maintenance of luteinizing hormone suppression through the 6-month treatment period of the lead-in study L-CP07-167 (NCT00635817) received the same treatment in this study that they were previously assigned in the lead-in study.

Treatment Period (36 Months)
Participant flow — Treatment Period (36 Months)
MilestoneLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Started3438
Completed1113
Not completed2325
Withdrew: Ready to enter puberty based on age1315
Withdrew: Other22
Withdrew: Personal reasons22
Withdrew: Withdrawal by subject04
Withdrew: Not adequately suppressed on therapy30
Withdrew: Lost to follow-up10
Withdrew: Protocol violation11
Withdrew: Therapeutic failure11
Safety Follow-up Period (12 Weeks)
Participant flow — Safety Follow-up Period (12 Weeks)
MilestoneLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Started2826
Completed2825
Not completed01
Withdrew: No longer needed treatment01

Outcome measures

PrimaryPercentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone

Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \< 4 mIU/mL. Peak-stimulated LH refers to the maximum LH concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Participants who failed suppression at previous visit and prematurely discontinued were counted as having failed future visits also. Final visit is the participant's last visit closest to Month 36.

Time frame:
Day 1, Months 6, 12, 24, and 36
Reported as:
Number · percentage of participants
Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone
percentage of participantsLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Day 1 [N= 32, 37]96.9 (83.78 to 99.92)100.0 (90.51 to 100.00)
Month 6 [N=32, 36]93.8 (79.19 to 99.23)100.0 (90.26 to 100.00)
Month 12 [N=31, 32]90.3 (74.25 to 97.96)96.9 (83.78 to 99.92)
Month 24 [N=16, 18]87.5 (64.65 to 98.45)100.0 (81.47 to 100.00)
Month 36 [N=9, 11]77.8 (39.99 to 97.19)100.0 (71.51 to 100.00)
Final Visit [N=33, 36]93.9 (79.77 to 99.26)100.0 (90.26 to 100.00)
SecondaryPercentage of Female Participants With Suppression of Basal Estradiol (Assay 1)

The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed before this change occurred, with an LLOQ of 1 pg/mL. Final visit is the participant's last visit closest to Month 36.

Time frame:
Day 1, Months 3, 6, 9, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Female Participants With Suppression of Basal Estradiol (Assay 1)
percentage of participantsLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Day 1 [N=28, 30]96.4 (81.65 to 99.91)100.0 (88.43 to 100.00)
Month 3 [N=29, 33]100.0 (88.06 to 100.00)100.0 (89.42 to 100.00)
Month 6 [N=26, 25]100.0 (86.77 to 100.00)100.0 (86.28 to 100.00)
Month 9 [N=18, 18]100.0 (81.47 to 100.00)100.0 (81.47 to 100.00)
Month 12 [N=10, 12]100.0 (69.15 to 100.00)100.0 (73.54 to 100.00)
Month 24 [N=1, 0]100.0 (2.50 to 100.00)NA (NA to NA)
Final Visit [N=31, 33]100.0 (88.78 to 100.00)100.0 (89.42 to 100.00)
SecondaryPercentage of Female Participants With Suppression of Basal Estradiol (Assay 2)

The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed after this change occurred, with an LLOQ of 10 pg/mL. Final visit is the participant's last visit closest to Month 36.

Time frame:
Months 6, 9, 12, 24, 30, and 36
Reported as:
Number · percentage of participants
Percentage of Female Participants With Suppression of Basal Estradiol (Assay 2)
percentage of participantsLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Month 6 [N=4, 6]100.0 (39.76 to 100.00)83.3 (35.88 to 99.58)
Month 9 [N=13, 10]61.5 (31.58 to 86.14)40.0 (12.16 to 73.76)
Month 12 [N=20, 15]45.0 (23.06 to 68.47)60.0 (32.29 to 83.66)
Month 24 [N=14, 15]50.0 (23.04 to 76.96)53.3 (26.59 to 78.73)
Month 30 [N=9, 15]33.3 (7.49 to 70.07)26.7 (7.79 to 55.10)
Month 36 [N=7, 11]28.6 (3.67 to 70.96)36.4 (10.93 to 69.21)
Final Visit [N=24, 26]29.2 (12.62 to 51.09)30.8 (14.33 to 51.79)
SecondaryPercentage of Male Participants With Suppression of Basal Testosterone

The percentage of male participants with suppression of basal testosterone to prepubertal levels, defined as testosterone \< 30 ng/dL. Final visit is the participant's last visit closest to Month 36.

Time frame:
Day 1, Months 3, 6, 9, 12, 24, 30, and 36
Reported as:
Number · percentage of participants
Percentage of Male Participants With Suppression of Basal Testosterone
percentage of participantsLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Day 1 [N= 2, 5]100.0 (15.81 to 100.00)100.0 (47.82 to 100.00)
Month 3 [N=2, 5]100.0 (15.81 to 100.00)100.0 (47.82 to 100.00)
Month 6 [N=2, 5]100.0 (15.81 to 100.00)80.0 (28.36 to 99.49)
Month 9 [N=2, 5]100.0 (15.81 to 100.00)80.0 (28.36 to 99.49)
Month 12 [N=1, 5]100.0 (2.50 to 100.00)100.0 (47.82 to 100.00)
Month 24 [N=1, 3]100.0 (2.50 to 100.00)66.7 (9.43 to 99.16)
Month 30 [N=0, 1]NA (NA to NA)100.0 (2.50 to 100.00)
Month 36 [N=0, 1]NA (NA to NA)100.0 (2.50 to 100.00)
Final Visit [N=2, 5]100.0 (15.81 to 100.00)100.0 (47.82 to 100.00)
SecondaryMean Peak-stimulated Luteinizing Hormone Concentration by Visit

Peak-stimulated luteinizing hormone refers to the maximum luteinizing hormone concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Final visit is the participant's last visit closest to Month 36.

Time frame:
Baseline of the lead-in study L-CP07-167, Day 1, Months 6, 12, 24, and 36
Reported as:
Mean · mIU/mL
Mean Peak-stimulated Luteinizing Hormone Concentration by Visit
mIU/mLLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Baseline [N=33, 38]21.89 ± 38.4610.16 ± 12.66
Day 1 [N=32, 37]2.00 ± 1.031.49 ± 0.86
Month 6 [N=32, 36]2.22 ± 1.161.62 ± 0.82
Month 12 [N=31, 32]2.24 ± 1.201.58 ± 1.02
Month 24 [N=14, 18]1.67 ± 0.970.88 ± 0.58
Month 36 [N=7, 11]1.51 ± 0.850.91 ± 0.49
Final Visit [N=33, 36]1.81 ± 1.131.15 ± 0.74
SecondaryPercentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)

The percentage of female participants with suppression of breast development. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression of breast development is defined as regression or no progression of breast development from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.

Time frame:
Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36
Reported as:
Number · percentage of participants
Percentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)
percentage of participantsLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Day 1 [N= 31, 31]90.3 (74.2 to 98.0)83.9 (66.3 to 94.5)
Month 3 [N=29, 31]86.2 (68.3 to 96.1)87.1 (70.2 to 96.4)
Month 6 [N=31, 30]90.3 (74.2 to 98.0)80.0 (61.4 to 92.3)
Month 9 [N=31, 28]87.1 (70.2 to 96.4)75.0 (55.1 to 89.3)
Month 12 [N=28, 26]85.7 (67.3 to 96.0)80.8 (60.6 to 93.4)
Month 18 [N=17, 20]82.4 (56.6 to 96.2)75.0 (50.9 to 91.3)
Month 24 [N=14, 16]78.6 (49.2 to 95.3)75.0 (47.6 to 92.7)
Month 30 [N=10, 16]90.0 (55.5 to 99.7)68.8 (41.3 to 89.0)
Month 36 [N=8, 12]87.5 (47.3 to 99.7)66.7 (34.9 to 90.1)
Final Visit [N=31, 31]83.9 (66.3 to 94.5)71.0 (52.0 to 85.8)
SecondaryPercentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)

The percentage of male participants with suppression of testicular volume and genital staging. Testicular volume was calculated from the length, width and height of each testicle measured by ultrasound. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression is defined as regression or no progression in both testicular volume and genital staging from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.

Time frame:
Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36
Reported as:
Number · percentage of participants
Percentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)
percentage of participantsLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Day 1 [N= 2, 5]50.0 (1.3 to 98.7)40.0 (5.3 to 85.3)
Month 3 [N=2, 5]50.0 (1.3 to 98.7)60.0 (14.7 to 94.7)
Month 6 [N=2, 5]50.0 (1.3 to 98.7)60.0 (14.7 to 94.7)
Month 9 [N=2, 5]50.0 (1.3 to 98.7)40.0 (5.3 to 85.3)
Month 12 [N=1, 5]100.0 (2.5 to 100.0)60.0 (14.7 to 94.7)
Month 18 [N=1, 3]100.0 (2.5 to 100.0)100.0 (29.2 to 100.0)
Month 24 [N=1, 3]100.0 (2.5 to 100.0)33.3 (0.8 to 90.6)
Month 30 [N=1, 1]100.0 (2.5 to 100.0)100.0 (2.5 to 100.0)
Month 36 [N=0, 1]NA (NA to NA)100.0 (2.5 to 100.0)
Final Visit [N=2, 5]50.0 (1.3 to 98.7)20.0 (0.5 to 71.6)
SecondaryChange From Baseline in Growth Rate

Baseline growth rate was the growth rate in the one year prior to Day 1 of the lead-in study L-CP07-167. Growth rates were calculated as the ratio of the change in height to the change in chronological age with an approximate 6-month interval for Day 1, Months 6, 12, 18, 24, 30, 36 and the Final Treatment Visit.

Time frame:
Baseline (the 1 year prior to the start of treatment in the lead-in study), and Day 1, Months 6, 12, 18, 24, 30, and 36
Reported as:
Mean · cm/year
Change From Baseline in Growth Rate
cm/yearLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Baseline [N=32, 38]7.2 ± 3.967.53 ± 2.81
Change from Baseline at Day 1 [N=32, 38]-1.67 ± 3.90-1.65 ± 3.43
Change from Baseline at Month 6 [N=32, 37]-1.66 ± 3.78-2.04 ± 2.95
Change from Baseline at Month 12 [N=28, 32]-1.99 ± 3.90-2.28 ± 2.88
Change from Baseline at Month 18 [N=18, 23]-2.21 ± 4.29-2.06 ± 2.40
Change from Baseline at Month 24 [N=15, 19]-2.36 ± 4.85-1.59 ± 2.20
Change from Baseline at Month 30 [N=11, 17]-1.86 ± 5.45-2.13 ± 2.33
Change from Baseline at Month 36 [N=8, 13]-2.64 ± 5.93-2.19 ± 2.41
Change from Baseline at Final Visit [N=32, 38]-2.27 ± 3.78-2.64 ± 2.65
SecondaryRatio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age

Bone age was determined by left hand/wrist bone age radiographs that were evaluated using the Fels Method by a central reader. The ratio of change from Baseline in bone age (BA)/change from Baseline in chronological age (CA) was calculated using the following formula: (BA at Post-baseline Treatment Visit - BA at Baseline) / (CA at Post-baseline Treatment Visit - CA at Baseline).

Time frame:
Baseline (of the lead-in study L-CP07-167), and Day 1, Months 12, 24, and 36
Reported as:
Mean · ratio
Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age
ratioLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
Day 1 [N=32, 37]0.51 ± 0.561.02 ± 1.27
Month 12 [N=32, 32]0.52 ± 0.330.62 ± 0.37
Month 24 [N=14, 17]0.53 ± 0.300.72 ± 0.34
Month 36 [N=5, 11]0.43 ± 0.150.64 ± 0.30
Final Visit [N=33, 32]0.48 ± 0.280.56 ± 0.30

Adverse events

Collected over 37 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate 3M Depot 11.25 mg—1/34 (2.9%)31/34 (91.2%)
Leuprolide Acetate 3M Depot 30 mg—0/38 (0%)31/38 (81.6%)
Most frequent serious events
Most frequent serious events
EventLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
INTRACRANIAL PRESSURE INCREASEDNervous system disorders1/340/38
Most frequent other events
Showing 10 of 35
Most frequent other events
EventLeuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mg
INJECTION SITE PAINGeneral disorders10/349/38
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations9/345/38
COUGHRespiratory, thoracic and mediastinal disorders4/349/38
PYREXIAGeneral disorders6/345/38
HEADACHENervous system disorders5/346/38
PHARYNGITIS STREPTOCOCCALInfections and infestations5/344/38
ARTHRALGIAMusculoskeletal and connective tissue disorders4/345/38
NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders3/345/38
GASTROENTERITISInfections and infestations4/344/38
VOMITINGGastrointestinal disorders0/344/38

Baseline characteristics

Participants who received at least 1 dose of study drug in this extension study.

Age, Continuous
Age, Continuous(years)Leuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mgTotal
Mean8.50 ± 1.718.45 ± 1.528.47 ± 1.60
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate 3M Depot 11.25 mgLeuprolide Acetate 3M Depot 30 mgTotal
Female323365
Male257
08

Study locations

20 sites
  • Site Reference ID/Investigator# 13521
    Birmingham, Alabama 35233, United States
  • Site Reference ID/Investigator# 14922
    Long Beach, California 90806, United States
  • Site Reference ID/Investigator# 26043
    Los Angeles, California 90027, United States
  • Site Reference ID/Investigator# 20802
    San Diego, California 92123, United States
  • Site Reference ID/Investigator# 22425
    Greenwood Village, Colorado 80111, United States
  • Site Reference ID/Investigator# 18181
    Jacksonville, Florida 32207, United States
  • Site Reference ID/Investigator# 26364
    Pensacola, Florida 32504, United States
  • Site Reference ID/Investigator# 26983
    Indianapolis, Indiana 46202, United States
  • Site Reference ID/Investigator# 20821
    Shreveport, Louisiana 71130-3932, United States
  • Site Reference ID/Investigator# 23643
    Minneapolis, Minnesota 55455, United States
  • Site Reference ID/Investigator# 23502
    St. Paul, Minnesota 55102, United States
  • Site Reference ID/Investigator# 14121
    Kansas City, Missouri 64108, United States
  • Site Reference ID/Investigator# 23802
    Oklahoma City, Oklahoma 73104, United States
  • Site Reference ID/Investigator# 13324
    Tulsa, Oklahoma 74135, United States
  • Site Reference ID/Investigator# 16506
    Hershey, Pennsylvania 17033, United States
  • Site Reference ID/Investigator# 14024
    Seattle, Washington 98104, United States
  • Site Reference ID/Investigator# 23182
    Bayamon, 00960, Puerto Rico
  • Site Reference ID/Investigator# 21721
    Ponce, 00717-2116, Puerto Rico
  • Site Reference ID/Investigator# 25908
    Rio Piedras, 00935, Puerto Rico
  • Site Reference ID/Investigator# 23082
    San Juan, 00936-8344, Puerto Rico
09

References and documents

Publications

  • Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab. 2014 Sep;99(9):3153-9. doi: 10.1210/jc.2013-4471. Epub 2014 Jun 13. PubMed 24926950 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Oct 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2008
First posted
Apr 28, 2008
Start
Dec 2008
Primary completionActual
Oct 2012
CompletionActual
Jan 2013
Results first posted
Dec 10, 2013
Last update
Jan 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00667446
Responsible party
Sponsor
First posted
Apr 28, 2008
Start date
Dec 2008
Primary completion
Oct 2012
Completion
Jan 2013
Results posted
Dec 10, 2013
Last update
Jan 9, 2014

Study contacts

Peter Bacher, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion